Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA yield high or low?
The EBITDA yield of 3.26% is in line with its estimated 1-year average of 3.04%, near the high end of its estimated 1-year range (2.80%–3.29%).
As of 2026-10-06T16:57:31.971Z.
Calculation as of: 2026-10-06T16:57:31.971Z.
Quote observation: 2026-10-06T16:55:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 347a41eedf46a91d1f1a35dde2c997a021a555167078676fef94c90a8032fb0d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
3.26%
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
6.35%
median of 205 covered companies
CURRENT VS SECTOR MEDIAN
-48.66%
vs the sector median at left
MiniMed Group, Inc. Common Stock
Market Cap
$5.52B
EBITDA Yield
3.26%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.30B
EBITDA Yield
3.47%
TTM Avg
10.75%
3Y Avg
10.29%
5Y Avg
10.29%
Market Cap
$5.76B
EBITDA Yield
1.83%
TTM Avg
1.65%
3Y Avg
1.60%
5Y Avg
1.99%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. Common Stock (MMED) | $5.52B | 3.26% | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | 4.61% | 4.21% | 4.87% | 6.47% |
| CG Oncology Inc. (CGON)vs › | $5.66B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.32B | 4.19% | 4.42% | 3.12% | 2.52% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.30B | 3.47% | 10.75% | 10.29% | 10.29% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.76B | 1.83% | 1.65% | 1.60% | 1.99% |
| Sotera Health Company (SHC)vs › | $5.27B | 7.97% | 7.78% | 7.69% | 7.17% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.19B | N/A | 8.18% | 5.23% | 5.23% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.18B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.92B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2026-10-05 | 3.17% |
| 2026-10-02 | 3.25% |
| 2026-10-01 | 3.27% |
| 2026-09-30 | 3.29% |
| 2026-09-29 | 3.19% |
| 2026-09-28 | 3.12% |
| 2026-09-25 | 3.20% |
| 2026-09-24 | 3.13% |
| 2026-09-23 | 3.11% |
| 2026-09-22 | 3.01% |
| 2026-09-21 | 3.02% |
| 2026-09-18 | 2.93% |
| 2026-09-17 | 2.90% |
| 2026-09-16 | 2.85% |
| 2026-09-15 | 2.90% |
| 2026-09-14 | 2.90% |
| 2026-09-11 | 2.83% |
| 2026-09-10 | 2.84% |
| 2026-09-09 | 2.80% |
